News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference


1/4/2013 6:38:22 AM

PLYMOUTH, Mich., Jan. 3, 2013 /PRNewswire/ -- Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that company founder Roger Newton, Ph.D., will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Dr. Newton's presentation will take place on Tuesday, January 8, at 3 PM PST in Elizabethan C/D Room 120 of the Westin St. Francis Hotel.

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize innovative, first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall cardiometabolic health. For more information, please visit www.esperion.com.

SOURCE Esperion Therapeutics, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES